Bio-Matrix Scientific Group Inc. Announces David Audley, the Founder of International Cellular Medicine Society, Has Joined the Advisory Board of Its Regen BioPharma Subsidiary

SAN DIEGO, CA--(Marketwire - June 15, 2012) - Bio-Matrix Scientific Group (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today the appointment of David Audley to the advisory board of Its Regen BioPharma subsidiary. Mr. Audley will advise Regen BioPharma on strategic leveraging of national and international clinical research resources. Mr. Audley is viewed by the Company as a key component in the commercialization of stem cell intellectual property. Additionally, it is anticipated that he will assist in raising international awareness for the regenerative therapies being developed by the Company.

In his function as executive director and CEO of the International Cellular Medicine Society (ICMS), Mr. Audley has spearheaded development and implementation of global guidelines for accreditation of stem cell clinics. Under his leadership, the ICMS has grown from a loose association of a handful of physicians to a major international standards organization with over 3500 members from 36 countries. He is a strong advocate for stem cell therapy development and implementation, and is the chief architect of the ICMS accreditation program that is currently evaluating the practices of nearly 20 facilities in a dozen countries. Mr. Audley also has strong professional relationships with Ministries of Health and governmental agencies in South America, Asia and the Middle East.

“My work at ICMS exposes me to the tremendous ability of stem cell therapeutics to alleviate human suffering. Unfortunately, business models have not caught up with the medical reality. Regen BioPharma is unique in that to my knowledge they are the first group to develop a model that accelerates development of stem cell therapeutics in a win-win situation for investors and patients,” said David Audley.

“Mr. Audley has made a substantial impact in the clinical translation of stem cell therapeutics by establishing standards, accreditations, an Institutional Review Board (IRB), and partnerships with major organizations such as the AABB,” said Christopher Mizer, President of Regen BioPharma. “We are extremely excited to work side by side with Mr. Audley in accelerating access of new stem cell therapies for patients.”

About Bio-Matrix Scientific Group, Inc. and Regen BioPharma, Inc.:

Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) is a biotechnology company focused on the development of regenerative medicine therapies and tools. The Company is focused on human therapies that address unmet medical needs. Specifically, Bio-Matrix Scientific Group, Inc. is looking to increase the quality of life through therapies involving stem cell treatments. These treatments are focused in areas relating to cardiovascular, hematology, oncology and other indications.

Through Its wholly owned subsidiary, Regen BioPharma, it is the Company’s goal to develop translational medicine platforms for the rapid commercialization of stem cell therapies. The Company is looking to use these translational medicine platforms to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the Company’s goal of increased quality of life. To follow our development, visit us at www.regenbiopharma.com.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.